Hoth Therapeutics Stock Net Income
| HOTH Stock | USD 1.26 0.02 1.56% |
Hoth Therapeutics fundamentals help investors to digest information that contributes to Hoth Therapeutics' financial success or failures. It also enables traders to predict the movement of Hoth Stock. The fundamental analysis module provides a way to measure Hoth Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hoth Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -8.7 M | -9.1 M | |
| Net Loss | -12.9 M | -12.2 M | |
| Net Loss | -7.1 M | -7.4 M | |
| Net Loss | (2.07) | (2.17) | |
| Net Income Per E B T | 0.92 | 0.81 |
Hoth | Net Income |
Hoth Therapeutics Company Net Income Analysis
Hoth Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Hoth Therapeutics Net Income | (7.85 M) |
Most of Hoth Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hoth Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Hoth Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Hoth Therapeutics is extremely important. It helps to project a fair market value of Hoth Stock properly, considering its historical fundamentals such as Net Income. Since Hoth Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Hoth Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Hoth Therapeutics' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Hoth Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Hoth Therapeutics reported net income of (7.85 Million). This is 102.3% lower than that of the Pharmaceuticals sector and 111.2% lower than that of the Health Care industry. The net income for all United States stocks is 101.37% higher than that of the company.
Hoth Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hoth Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Hoth Therapeutics could also be used in its relative valuation, which is a method of valuing Hoth Therapeutics by comparing valuation metrics of similar companies.Hoth Therapeutics is currently under evaluation in net income category among its peers.
Hoth Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Hoth Therapeutics from analyzing Hoth Therapeutics' financial statements. These drivers represent accounts that assess Hoth Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Hoth Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 29.3M | 14.7M | 9.3M | 4.9M | 5.6M | 5.4M | |
| Enterprise Value | 26.7M | 6.2M | 2.9M | (4.3M) | (5.0M) | (4.7M) |
Hoth Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Hoth Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Hoth Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Hoth Therapeutics' value.| Shares | Wells Fargo & Co | 2024-09-30 | 2.0 | Qube Research & Technologies | 2024-09-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 0.0 | Hrt Financial Llc | 2024-09-30 | 121.9 K | Geode Capital Management, Llc | 2024-09-30 | 82.9 K | Ubs Group Ag | 2024-09-30 | 56.5 K | Vanguard Group Inc | 2024-09-30 | 38.8 K | Virtu Financial Llc | 2024-09-30 | 32.6 K | Two Sigma Securities, Llc | 2024-09-30 | 18.6 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 10.3 K | Tower Research Capital Llc | 2024-09-30 | 4.5 K |
Hoth Fundamentals
| Return On Equity | -0.83 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | 571.76 K | ||||
| Shares Outstanding | 6.9 M | ||||
| Shares Owned By Insiders | 0.92 % | ||||
| Shares Owned By Institutions | 5.52 % | ||||
| Number Of Shares Shorted | 659.22 K | ||||
| Price To Earning | (7.16) X | ||||
| Price To Book | 1.14 X | ||||
| EBITDA | (153.15 K) | ||||
| Net Income | (7.85 M) | ||||
| Cash And Equivalents | 11.62 M | ||||
| Cash Per Share | 9.02 X | ||||
| Total Debt | 55.16 K | ||||
| Debt To Equity | 2.01 % | ||||
| Current Ratio | 15.74 X | ||||
| Book Value Per Share | 1.09 X | ||||
| Cash Flow From Operations | (8.45 M) | ||||
| Short Ratio | 0.03 X | ||||
| Earnings Per Share | (1.27) X | ||||
| Target Price | 4.5 | ||||
| Beta | 0.84 | ||||
| Market Capitalization | 8.84 M | ||||
| Total Asset | 9.52 M | ||||
| Retained Earnings | (52.94 M) | ||||
| Working Capital | 8.75 M | ||||
| Current Asset | 448.84 K | ||||
| Current Liabilities | 312.22 K | ||||
| Net Asset | 9.52 M |
About Hoth Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hoth Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hoth Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hoth Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Check out Hoth Therapeutics Piotroski F Score and Hoth Therapeutics Altman Z Score analysis. For more detail on how to invest in Hoth Stock please use our How to Invest in Hoth Therapeutics guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hoth Therapeutics. If investors know Hoth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hoth Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Hoth Therapeutics is measured differently than its book value, which is the value of Hoth that is recorded on the company's balance sheet. Investors also form their own opinion of Hoth Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Hoth Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hoth Therapeutics' market value can be influenced by many factors that don't directly affect Hoth Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hoth Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hoth Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hoth Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.